Objectives: Compare outcomes in patients with suspected heart failure (HF) and raised natriuretic peptides who are reviewed in a specialist HF clinic in line with NICE guidelines (Compliant group) versus patients who are not reviewed in the clinic (Non-compliant group).
Strengths and limitations of this study
There are few data supporting the 2 and 6-week waiting-time targets for specialist assessment recommended by NICE for patients in primary care with suspected HF.
This study examines whether adhering to the NICE guidelines is associated with better patient outcomes and therefore provides some insight into the potential benefits of guideline implementation.
The data are observational and therefore causation and association cannot be fully separated.
F o r p e e r r e v i e w o n l y
Introduction
Heart failure (HF) is a common, severe, chronic disease. It causes significant morbidity and has a poor prognosis characterised by multiple hospital admissions and death with associated implications both for patients' quality of life and resources. In the UK approximately 900,000 people are affected. [1] HF accounts for around 5% of all emergency medical admissions and 2% of all NHS inpatient bed-days. [2] Despite the availability of evidence-based treatments which improve prognosis (particularly for patients with HF and reduced ejection fraction-HFREF) contemporary data demonstrate outcomes in acute and chronic HF that still compare unfavourably to many cancers. [2] [3] [4] In recognition of these poor outcomes, the UK's National Institute for Health and Care Excellence (NICE) introduced chronic heart failure guidelines (CG108) [2] and quality standards [5] to improve HF care.
These guidelines recommend that patients with suspected HF are referred for a timely diagnosis through specialist assessment and trans-thoracic echocardiography. A specialist is defined as "a doctor with subspecialty interest in heart failure (often a consultant cardiologist) who leads a specialist multidisciplinary heart failure team of professionals".
Those with a history of prior myocardial infarction or very high natriuretic peptide levels (BNP>400pg/ml or NT-proBNP>2000pg/ml) should be seen within 2 weeks and patients with more modest elevations in natriuretic peptides (BNP>100pg/ml or NT-proBNP>400pg/ml)
should be seen within 6 weeks. Patients with natriuretic peptide levels below these thresholds should be investigated for alternative diagnoses. Whilst specialist care for patients with HF has been repeatedly shown to improve patient outcomes [6, 7] there are a paucity of data to support this waiting time based referral pathway which is modelled on similar NICE referral pathways for patients with suspected cancer. [8] Moreover, this cancer waiting time target is itself arbitrary and it is unclear whether adherence to it results in better outcomes. [9] Following the publication of the NICE chronic HF guidelines, a dedicated one-stop, fully NICE compliant referral pathway and specialist clinic was established at our institution to assess patients with suspected HF. The clinic launch was accompanied by education of referring general practitioners (GPs) and provision of NT-proBNP assays. Despite this, not all patients with suspected HF were referred to secondary care but were managed in non-specialist primary care settings, and thus not in compliance with guidelines. Our aim was to compare 
Methods
This was a single centre, retrospective evaluation of outcomes in patients with suspected HF conducted at Portsmouth Hospitals NHS Trust, a very large district general hospital serving a population of 675,000 on the south coast of England.
Referrals to the specialist HF clinic were sent via a dedicated fax number. Patients referred with an NT-proBNP of >2000pg/ml were seen within 2 weeks and those with an NT-proBNP of 400-2000pg/ml within 6 weeks in keeping with NICE guidelines. Participants were seen in a one-stop clinic and received specialist assessment, echocardiography, diagnosis, and a management plan. Patients with HF were managed in line with the ESC HF guidelines [10] wherever possible and appropriate. Those with HFREF routinely received early and ongoing management from a multidisciplinary team (MDT) centred around community-based HF nurse specialists and supported by HF specialists. Those with a diagnosis of HFPEF and those without HF were usually discharged back to the GP with a management plan.
All patients with a raised NT-proBNP sample processed at our laboratory during the first 8 months of the specialist HF clinic operating (February to September 2014) were identified.
The biochemistry laboratory at the hospital is the central laboratory that processes all the samples from the GP practices in the surrounding area. Serum samples were processed using a Biomerieux sandwich immunoassay which measures NT-proBNP over a range of 15-25,000pg/ml. Participants were divided into 2 groups; those referred to the HF clinic (Compliant group) and those who were not referred to the clinic (Non-Compliant group).
Hospital coding data, information services, electronic records and case notes were used to identify hospital admissions, reason for admission and deaths in all patients over a minimum follow up period of 6-months from the time of the raised NT-proBNP result.
Individual case note assessment was performed if further information was required.
Comparisons were then made between the two cohorts. 
Results

Patient population
567 consecutive patients with a raised NT-proBNP were identified and included; 161 (28%) in the Compliant group and 406 (72%) in the Non-Compliant group. The mean follow-up period was 9±2 months.
The Compliant group patients were slightly younger and had much higher NT pro BNP than the Non-Compliant group. Baseline characteristics of the patients are shown in table 1. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o according to whether they were compliant with NICE recommendations to refer for specialist evaluation.
NICE-compliant patient pathway
68/161 (42%) of patients had an NT-proBNP>2000pg/ml and were on the 2-week pathway.
67/68 (99%) were offered an appointment within the 2-week target. 4 of these patients declined the first appointment offered therefore overall 63/68 (93%) were seen within 2-weeks (table 2) . 92 of the 93 (99%) patients on the 6-week pathway were offered and accepted an appointment within 6-weeks. 3 (2%) patients were admitted to hospital after the positive NT-proBNP result but before they were due to be reviewed in clinic but were still included as part of the Compliant group. They included 2 (3%) patients on the 2-week pathway and 1 (1%) patient on the 6-week pathway. 1 of these patients, who was on the 2-week pathway, died during that admission.
116 (72%) patients experienced delays in the pathway. Mean NT-proBNP in those patients who were delayed was 3521±5138pg/ml compared to 2043±1785pg/ml in those who were not. Delays in the pathway were not associated with a worse outcome. Interval between NT-proBNP and referral (days)
13±12 19±17
Interval between referral and clinic review (days)
10±5 24±12
Discussion
This service evaluation demonstrates that patients with suspected HF and raised natriuretic peptides have a very high rate of adverse outcomes in the short term. Timely HF specialist involvement is associated with better outcomes, specifically lower rates of hospitalisation.
These novel, real-world data support the implementation of HF pathways which comply with NICE guidelines.
The main strengths of this work are that this is a systematic evaluation of consecutive realworld patients with suspected HF and that those referred to specialist services received guideline-based treatment delivered by an established comprehensive HF service. It also provides valuable contemporary data from a cohort representative of a very large population of patients with poor outcomes who remain under-studied. Furthermore, whilst NICE recommendations on referral pathways were produced because of the adverse The main limitation of the data is that they are retrospective and observational and therefore demonstrate an association rather than clear causation. There will be some unadjusted confounding factors and the possibility of referral bias influencing outcomes.
However, whilst the Non-compliant group were slightly older, the compliant group had much higher NT-proBNP levels, which itself is independently associated with a higher risk of adverse outcomes. [11] The much lower hospitalisation rates seen in the Compliant group therefore suggests that there is a real benefit in being seen in a specialist HF clinic.
These findings are consistent with the substantial body of evidence demonstrating that outcomes for patients with HF are improved within appropriate systems of care.
[6]
Specialist multidisciplinary care reduces both all-cause and HF hospitalisation. [7] Furthermore, in contrast to many drug and device therapies, the literature suggests that all patients with HF, including those with HFPEF, benefit from specialist care. Again, our data are consistent with this in that we included all patients regardless of left ventricular ejection fraction. The lower rates of hospitalisation observed in the Compliant patients is likely to be due, at least in part, to specialist care. Expert care involves accurate diagnosis and management including appropriate use of therapies which improve outcomes. Given the short follow-up period of this study, drug therapies will have been the most important interventions and have previously been well-documented to reduce hospitalisations over short follow-up periods for patients with HFREF. [10] An additional benefit for Compliant HF patients, and in particular those with HFREF in this study, is likely to relate to ongoing access to the multidisciplinary team. Patients in the Non-compliant group would have been much less likely to be managed by the multidisciplinary team who receive the vast majority of new referrals from specialists.
Since raised natriuretic peptides are known to predict an adverse outcome in patients without overt HF as well as in those with HF [11, 12] it is likely that better outcomes in the Compliant group are not solely due to better management of HF. For example, HF physicians are also well placed to manage other cardiovascular diseases, such as atrial fibrillation, which can mimic HF and causes elevations in natriuretic peptides. We did not individually evaluate the causes for each admission however it seems likely that early assessment by a physician led to changes in management for patients without HF in hospitalisation, they may also be recorded as being hospitalised due to fluid overload-a non-CV cause. Misclassification of some causes of hospitalisation may be more likely as nonclinical administrative staff record hospitalisation causes in our institution, a practice which is the norm in the UK.
The low referral rate (28%) of patients with raised natriuretic peptides is noteworthy. More detailed data on those patients who were not referred are not available. However, the local healthcare provision is organised such that our centre provides the vast majority of secondary care, and thus specialist services including cardiology and HF. A small minority of patients may have been referred elsewhere, such as to the private sector. However, it can be reasonably assumed that most of the Non-compliant patients were managed in primary care by their GP. As the HF pathway was established shortly before this evaluation commenced some GPs may not have known about the service despite our efforts to raise awareness and the incorporation of the referral pathway into their standard online resources. It is also likely that in many cases GPs underestimate the severity and complexity of HF and felt they could manage these patients themselves. Contemporary data suggest that GPs have relatively high levels of confidence in the diagnosis and management of HF. [13] Some patients may have chosen against referral but again this is likely to account for a small proportion of the Non-compliant patients.
The purpose of including referral-time targets in the NICE guidelines is so that patients with suspected HF are seen rapidly as they are at high risk of adverse outcome. Despite offering a service compliant with these targets we identified notable delays between a positive NTproBNP result in primary care and referral to clinic. For those on the 2-week pathway the interval between a positive NT-proBNP and referral to the HF clinic was longer than the interval between receipt of the referral and patient review in clinic. This seems counterproductive and unnecessary in a time-critical pathway but was not associated with worse The true magnitude of the benefit of early specialist review for patients with suspected HF and raised natriuretic peptides needs to be clarified. The body of evidence supporting specialist care for HF patients means that it would be difficult to justify a randomised controlled trial that would deliberately put patients at risk. However, it may be possible to compare outcomes in regions with no established NICE compliant services to other areas with established compliant services. Our findings are in keeping with the totality of the evidence and provide further data supporting specialist care. However, since it is a single centre study, there may be centre specific effects at work and it is important to demonstrate that these findings can be reproduced in multiple centres. Subgroup analysis has been deliberately limited to prevent analysis of small groups and reduce the likelihood of spurious findings. As a result, the benefits of specialist review for particular patient subgroups, for example those with HFREF versus HFPEF, are not known from these data.
The growing HF burden means that further research to build on this work and answer these questions should be considered an urgent priority.
Conclusion
This study confirms that real world patients with suspected HF and raised natriuretic peptides have an adverse short-term prognosis with high rates of hospitalisations and mortality. NICE chronic HF recommendations were created in recognition of this however data supporting the implementation of the diagnostic aspects of these guidelines have been lacking. Specialist care improves outcomes for all HF patients and an early review for patients with suspected HF in a NICE compliant clinic is associated with reduced rates of allcause hospitalisation. Centres offering a comprehensive HF service should set up pathways in line with NICE recommendations and GPs should be encouraged to refer to these services. 
Data sharing statement
No additional data available
Funding
This research received no specific grant from any funding agency in the public, commercial
or not-for-profit sectors.
Competing interests
There are no relevant competing interests. Design: Retrospective observational study.
Setting: Single large UK district general hospital.
Participants: 567 consecutive patients in primary care with a raised NT-proBNP (>400 pg/ml) from February to September 2014.
Interventions: 161 (28%) patients were referred to the specialist HF clinic and 406 (72%) were not. Outcomes were compared between the two groups.
Outcome measures: All cause and cardiovascular (CV)-hospitalisations and all-cause mortality.
Results:
The Compliant group were slightly younger than the Non-compliant group (78±9 vs.
80±9; p=0.019) but had much higher NTproBNP (3108±4526 vs. 2271±3637pg/ml; p<0.0001). Despite this, over a mean follow up period of 9±2 months, rates of all-cause hospitalisation (24% vs. 44%; p<0.0001), and CV hospitalisation (3% vs. 15% p<0.0001) were significantly lower in the Compliant group vs. the Non-compliant group respectively. There was no significant difference in mortality rates (6% Compliant group vs. 8% Non-compliant group; p=0.487).
Conclusions:
Hospitalisation rates in patients with suspected heart failure and raised NTproBNP were extremely high over a relatively short follow up period. Patients reviewed in a specialist HF clinic had much higher NTproBNP levels, suggesting they were at higher risk of adverse outcomes, yet also had significantly lower rates of all cause and CV hospitalisation. Our findings support implementation of the relevant NICE guidelines for patients with suspected HF. 
Strengths and limitations of this study
The data are observational and therefore causation and association cannot be fully separated. These guidelines recommend that patients with suspected HF are referred for a timely diagnosis through specialist assessment and trans-thoracic echocardiography. A specialist is defined as "a doctor with subspecialty interest in heart failure (often a consultant cardiologist) who leads a specialist multidisciplinary heart failure team of professionals".
should be seen within 6 weeks. Patients with natriuretic peptide levels below these thresholds should be investigated for alternative diagnoses. Whilst specialist care for patients with HF has been repeatedly shown to improve patient outcomes [6, 7] there are a paucity of data to support this waiting time based referral pathway which is modelled on similar NICE referral pathways for patients with suspected cancer. [8] Moreover, this cancer waiting time target is itself arbitrary and it is unclear whether adherence to it results in better outcomes. [9] Following the publication of the NICE chronic HF guidelines, a dedicated one-stop, fully NICE compliant referral pathway and specialist clinic was established at our institution to assess patients with suspected HF. The clinic launch was accompanied by education of referring general practitioners (GPs) and provision of NT-proBNP assays. Despite this, not all patients with suspected HF were referred to secondary care but were managed in non-specialist primary care settings, and thus not in compliance with guidelines. Our aim was to compare Those with a diagnosis of HFPEF and those without HF were usually discharged back to the GP with a management plan.
The biochemistry laboratory at the hospital is the central laboratory that processes all the samples from the GP practices in the surrounding area. Serum samples were processed Hospital coding data, information services, electronic records and case notes were used to identify hospital admissions, reason for admission and deaths in all patients over a minimum follow up period of 6-months from the time of the raised NT-proBNP result.
Comparisons were then made between the two cohorts.
Secondary comparisons in hospitalisation and mortality rates were made within the NICE compliant group between those whose assessment was delayed and those whose assessment was not delayed. In patients with an NT-proBNP of 400-2000pg/ml, a delay was defined as either an interval between the positive blood test result and referral of >10days
or between referral and a clinic appointment date offer of >6 weeks. In patients with an NTproBNP of >2000pg/ml this was defined as >5 days or 2 weeks respectively.
Formal ethical approval was not required however the study was registered with the Trust's Clinical Effectiveness Department.
Microsoft Excel with XLSTAT software was used for all statistical analyses. Data are presented as mean ± SD. For continuous variables Shapiro-Wilk analyses checked normality of the underlying distribution. Having determined that nonparametric tests were required the two groups were compared using either the Mann Whitney U test or the Fisher exact test for binomial data. Significance was determined if two-sided p-values were <0.05.
Patient and Public Involvement
Patients and the public were not directly involved in the study development, design, recruitment or conduct. The results will be disseminated to primary care locally. .
NICE-compliant patient pathway
116 (72%) patients experienced delays in the pathway. Mean NT-proBNP in those patients who were delayed was 3521±5138pg/ml compared to 2043±1785pg/ml in those who were not. Delays in the pathway were not associated with a worse outcome. There were no differences in all-cause hospitalisations: 12 (26%) versus 27 (23%), p=0.68; CV admissions: 2 (4%) versus 3 (3%), p=0.619; or deaths: 1 (2%) versus 9 (8%) p=0.285, for those not delayed versus those delayed respectively.
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Discussion
The main strengths of this work are that this is a systematic evaluation of consecutive realworld patients with suspected HF and that those referred to specialist services received guideline-based treatment delivered by an established comprehensive HF service. It also provides valuable contemporary data from a cohort representative of a very large population of patients with poor outcomes who remain under-studied. Furthermore, whilst NICE recommendations on referral pathways were produced because of the adverse outcomes in this population, the waiting-time targets predate relevant supporting evidence.
The main limitation of the data is that they are retrospective and observational and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
therefore demonstrate an association rather than clear causation. There will be some unadjusted confounding factors and the possibility of referral bias influencing outcomes.
Since raised natriuretic peptides are known to predict an adverse outcome in patients without overt HF as well as in those with HF [11, 12] it is likely that better outcomes in the The low referral rate (28%) of patients with raised natriuretic peptides is noteworthy. More detailed data on those patients who were not referred are not available. However, the local healthcare provision is organised such that our centre provides the vast majority of secondary care, and thus specialist services including cardiology and HF. A small minority of patients may have been referred elsewhere, such as to the private sector. However, it can be reasonably assumed that most of the Non-compliant patients were managed in primary care by their GP. As the HF pathway was established shortly before this evaluation commenced some GPs may not have known about the service despite our efforts to raise awareness and the incorporation of the referral pathway into their standard online resources. It is also likely that in many cases GPs underestimate the severity and complexity of HF and felt they could manage these patients themselves. Contemporary data suggest that GPs have relatively high levels of confidence in the diagnosis and management of HF. [13] Another reason for the relatively low referral rate may relate to GPs testing patients in the Non-compliant group in clinical situations outwith the pathway. Our pathway specified that natriuretic peptide levels should only be checked for patients with a potential new diagnosis of HF in keeping with NICE guidelines. However, NTproBNP may, in some cases, have been used to monitor patients with known HF or even in the absence of a clinical suspicion of HF. Some patients may also have chosen against referral but again this is likely to account for a small proportion of the Non-compliant patients.
The purpose of including referral-time targets in the NICE guidelines is so that patients with suspected HF are seen rapidly as they are at high risk of adverse outcome. Despite offering a service compliant with these targets we identified notable delays between a positive NTproBNP result in primary care and referral to clinic. For those on the 2-week pathway the interval between a positive NT-proBNP and referral to the HF clinic was longer than the interval between receipt of the referral and patient review in clinic. This seems counterproductive and unnecessary in a time-critical pathway but was not associated with worse outcomes. The absence of worse outcomes in patients who were delayed may be due to the low numbers who did not experience a delay or because rapid specialist review compensated for what were relatively short delays experienced earlier in the pathway.
The true magnitude of the benefit of early specialist review for patients with suspected HF and raised natriuretic peptides needs to be clarified. The body of evidence supporting specialist care for HF patients means that it would be difficult to justify a randomised controlled trial that would deliberately put patients at risk. However, it may be possible to compare outcomes in regions with no established NICE compliant services to other areas with established compliant services. Our findings are in keeping with the totality of the evidence and provide further data supporting specialist care. However, since it is a single centre study, there may be centre specific effects at work and it is important to demonstrate that these findings can be reproduced in multiple centres. Subgroup analysis has been deliberately limited to prevent analysis of small groups and reduce the likelihood of spurious findings. As a result, the benefits of specialist review for particular patient subgroups, for example those with HFREF versus HFPEF, are not known from these data.
Conclusion
This study confirms that real world patients with suspected HF and raised natriuretic peptides have an adverse short-term prognosis with high rates of hospitalisations and mortality. NICE chronic HF recommendations were created in recognition of this however data supporting the implementation of the diagnostic aspects of these guidelines have been lacking. Specialist care improves outcomes for all HF patients and an early review for patients with suspected HF in a NICE compliant clinic is associated with reduced rates of allcause hospitalisation. Centres offering a comprehensive HF service should set up pathways 
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